Please login to the form below

Not currently logged in
Email:
Password:

inflammatory conditions

This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.

Reference price bill tabled in US House and Senate

Reference price bill tabled in US House and Senate

Adopting this policy would slash the monthly cost of AbbVie’s Humira for arthritis and other inflammatory conditions to $1, 576 from $2, 770, say the bills, which also lists potential

Latest news

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Our research in NASH dates back more than a decade and stems directly from how we have developed medicines to address conditions that put patients at risk for NASH, including type ... We are confident that by drawing from our history and deep

  • Gilead and Galapagos JAK contender scores in RA trial Gilead and Galapagos JAK contender scores in RA trial

    The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis.

  • Sanofi and Ablynx sign €2.4bn nanobody deal Sanofi and Ablynx sign €2.4bn nanobody deal

    The partners will focus on developing and commercialising nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases (IMID). ... Through external partnerships like these, combined with our internal R&D expertise, we

  • FDA verdict on Amgen's Humira biosimilar due in September FDA verdict on Amgen's Humira biosimilar due in September

    Begins review the version of AbbVie's big-selling anti-inflammatory drug. The US FDA has started its review of Amgen's biosimilar version of big-selling anti-inflammatory drug Humira, ... Sean Harper, Amgen's executive vice president of R&D, said: "If

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    Anti-Inflammatory deal. After jettisoning the Polyphor project, Roche added another research deal in the form of a licensing agreement for a novel, oral small molecule inhibitor of Vascular Adhesion Protein ... patients with various inflammatory

More from news
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    Here we consider how the European landscape for biosimilars is ripe for transformation as more mAbs or anti-TNFs (Tumour Necrosis Factors) for inflammatory conditions such as rheumatoid arthritis enter the

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics